![]() |
| The FAST system measures tumor size regression and is a new way to test the efficacy of cancer drugs. Image credit: Alex Abramson, Bao Group, Stanford University |
Electronically sensitive, skin-like membrane can measure changes in tumor size to the hundredth of a millimeter. It represents a new, faster, and more accurate approach to screen cancer drugs.
Engineers at Stanford University have created a small, autonomous device with a stretchable and flexible sensor that can be adhered to the skin to measure the changing size of tumors below. The non-invasive, battery-operated device is sensitive to one-hundredth of a millimeter (10 micrometers) and can beam results to a smartphone app wirelessly in real time with the press of a button.
In practical terms, the researchers say, their device – dubbed FAST for “Flexible Autonomous Sensor measuring Tumors” – represents a wholly new, fast, inexpensive, hands-free, and accurate way to test the efficacy of cancer drugs. On a grander scale, it could lead to promising new directions in cancer treatment. FAST is detailed in a paper published Sept. 16 in Science Advances.
Each year researchers test thousands of potential cancer drugs on mice with subcutaneous tumors. Few make it to human patients, and the process for finding new therapies is slow because technologies for measuring tumor regression from drug treatment take weeks to read out a response. The inherent biological variation of tumors, the shortcomings of existing measuring approaches, and the relatively small sample sizes make drug screenings difficult and labor-intensive.








